potassium voltage-gated channel subfamily B member 1Genealiases: DEE26 · DRK1 · Kv2.1
Q-omics provides the consensus-scored KCNB1 profile across patient tissues and cancer cell-line models. KCNB1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNB1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, KCNB1 RNA expression shows 16,091 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, BLCA, and PCPG as cancer lineages where KCNB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNB1 survival associations across molecular data types. KCNB1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNB1 RNA expression–survival associations across cancer types. High KCNB1 expression shows unfavorable associations in BLCA and UVM, but favorable associations in KIRC, LGG, PAAD and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNB1 RNA expression.
This table summarizes KCNB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCNB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNB1 shows lower tumor expression in BLCA, COAD, THCA, KICH, UCEC and HNSC. The BLCA box plot shows higher KCNB1 RNA expression in normal versus tumor tissue (log2 FC = −1.817, t-test p < 0.001).
This table shows molecular features associated with KCNB1 in patient tissues and cancer cell lines. In patient samples, KCNB1 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
